欧州の造影剤およびインジェクターシステム市場：分析・予測 (2022-2026年)

欧州の造影剤およびインジェクターシステムの市場規模は、2022年の21億4,150万米ドルから、予測期間中は6.36%のCAGRで推移し、2026年には27億4,060万米ドルの規模に成長すると予測されています。

欧州の造影剤およびインジェクターシステム市場：イントロダクション

欧州の造影剤およびインジェクターシステム市場は、慢性疾患の増加、画像診断への需要の増加、医療画像技術の進歩などの要因によって力強い成長を遂げています。造影剤およびインジェクターシステムは、CTスキャン、MRIスキャン、血管造影などの画像診断において、解剖学的構造の可視性を高める上で重要な役割を果たしています。高齢化社会の進展と医療費の増加に伴い、疾病の早期発見と正確な診断が重視されるようになり、欧州における造影剤およびインジェクターシステムへの需要はさらに高まっています。さらに、画像診断技術の向上と患者の予後の改善を目指したR&Dが進行しており、市場成長の原動力となることが期待されています。また、患者の安全確保と革新的な画像ソリューションの提供を目的とした規制上の取り組みも、同地域の市場拡大に寄与しています。

当レポートでは、欧州の造影剤およびインジェクターシステムの市場を調査し、市場概要、法規制環境、特許動向、市場影響因子の分析、市場規模の推移・予測、競合情勢、主要企業の分析などをまとめています。

市場の分類

セグメンテーション1：製品別

• 造影剤
• インジェクターシステム

セグメンテーション：インジェクターシステム（製品別）

• インジェクター
• 消耗品・付属品

セグメンテーション2：国別

• ドイツ
• 英国
• フランス
• イタリア
• スペイン
• その他

目次

エグゼクティブサマリー

調査範囲

第1章 市場

• 市場の見通し
  • 製品の定義
  • 包含基準と除外基準
  • 主な調査結果
• 市場概要
• 業界の展望
  • 規制および法的要件と枠組み
  • 特許分析
  • 主要動向
• COVID-19が造影剤およびインジェクターシステム市場に与える影響
• 市場力学
  • 影響分析
  • 市場促進要因
  • 市場抑制要因
  • 市場機会

第2章 地域

• 概要
• 欧州
  • 主な調査結果
  • 市場力学
  • 市場規模・予測

第3章 市場-競合ベンチマーキングと企業プロファイル

• 競合ベンチマーキング
  • 主要な戦略・展開
  • 市場シェア分析
• 造影剤エコシステムのアクティブ企業
• 企業プロファイル
  • Bayer AG
  • Bracco Group
  • Fresenius SE & Co. KGaA
  • Guerbet
  • ulrich GmbH & Co. KG

List of Figures

• Figure 1: Europe Contrast Media Agent and Injector System Market, $Million, 2021-2026
• Figure 2: Contrast Media Agent and Injector System Market, Impact Analysis
• Figure 3: Europe Contrast Media Agent and Injector System Market (by Product), $Million, 2021 and 2026
• Figure 4: Contrast Media Agent and Injector System Market: Research Methodology
• Figure 5: Primary Research Methodology
• Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 7: Top-Down Approach (Segment-Wise Analysis)
• Figure 8: Contrast Media Agent and Injector System Market, Patent Analysis (by Year), January 2018-May 2022
• Figure 9: Contrast Media Agent and Injector System Market, Patent Analysis (by Country), January 2018-May 2022
• Figure 10: Number of CT Scans Per One Million Inhabitants in the U.S., 2015, 2017, and 2019
• Figure 11: Number of CT Scans Per One Million Inhabitants in Europe (by Country), 2015, 2017, and 2019
• Figure 12: Number of CT Scans Per One Million Inhabitants in Asia-Pacific (by Country), 2015, 2017, and 2019
• Figure 13: Number of CT Scans Per One Million Inhabitants, 2018-2020
• Figure 14: Number of Scans by Imaging Modalities in the U.K. from 2018-2019 to 2020-2021, Million
• Figure 15: Contrast Media Agent and Injector System Market, Impact Analysis
• Figure 16: Expected Number of Cancer Cases, Globally, 2020, 2025, 2030, 2035, and 2040
• Figure 17: Incidence of Cardiovascular Disease, 2015 - 2019, Million
• Figure 18: Innovative Vendors Product Solutions
• Figure 19: Contrast Media Agent and Injector System Market (by Region), % Share, 2021-2026
• Figure 20: Europe Contrast Media Agent and Injector System Market, $Million, 2021-2026
• Figure 21: Europe Contrast Media Agent and Injector System Market (by Product), $Million, 2021-2026
• Figure 22: Europe Contrast Media Injector System Market (by Product), $Million, 2021-2026
• Figure 23: Europe Contrast Media Agent and Injector System Market (by Country), % Share, 2021 and 2026
• Figure 24: Germany Contrast Media Agent and Injector System Market, $Million, 2021-2026
• Figure 25: Germany Contrast Media Agent and Injector System Market (by Product), $Million, 2021-2026
• Figure 26: Germany Contrast Media Injector System Market (by Product), $Million, 2021-2026
• Figure 27: Italy Contrast Media Agent and Injector System Market, $Million, 2021-2026
• Figure 28: Italy Contrast Media Agent and Injector System Market (by Product), $Million, 2021-2026
• Figure 29: Italy Contrast Media Injector System Market (by Product), $Million, 2021-2026
• Figure 30: France Contrast Media Agent and Injector System Market, $Million, 2021-2026
• Figure 31: France Contrast Media Agent and Injector System Market (by Product), $Million, 2021-2026
• Figure 32: France Contrast Media Injector System Market (by Product), $Million, 2021-2026
• Figure 33: Number of Scans by Imaging Modalities in the U.K. from 2015-2016 to 2020-2021, Million
• Figure 34: U.K. Contrast Media Agent and Injector System Market, $Million, 2021-2026
• Figure 35: U.K. Contrast Media Agent and Injector System Market (by Product), $Million, 2021-2026
• Figure 36: U.K. Contrast Media Injector System Market (by Product), $Million, 2021-2026
• Figure 37: Number of CT Scanners in Spain per One Million Inhabitants, 2014-2020
• Figure 38: Spain Contrast Media Agent and Injector System Market, $Million, 2021-2026
• Figure 39: Spain Contrast Media Agent and Injector System Market (by Product), $Million, 2021-2026
• Figure 40: Spain Contrast Media and Injector System Market (by Product), $Million, 2021-2026
• Figure 41: Rest-of-Europe Contrast Media Agent and Injector System Market, $Million, 2022-2026
• Figure 42: Rest-of-Europe Contrast Media Agent and Injector System Market (by Product), $Million, 2021-2026
• Figure 43: Rest-of-Europe Contrast Media Injector System Market (by Product), $Million, 2021-2026
• Figure 44: Contrast Media Agent and Injector System Market, Number of Key Developments and Strategies, January 2018-May 2023
• Figure 45: Regulatory and Legal Activities, January 2018-May 2023
• Figure 46: Partnerships, Collaborations, and Business Expansions, January 2018-May 2023
• Figure 47: Mergers and Acquisitions, January 2018-May 2023
• Figure 48: New Offerings, January 2018-May 2023
• Figure 49: Contrast Media Agent Market, Company Revenue Share Analysis, $Million, 2021
• Figure 50: Contrast Media Injector System Market, Company Revenue Share Analysis, $Million, 2021
• Figure 51: Bayer AG: Product Portfolio
• Figure 52: Bayer AG: Overall Financials, $Million, 2020-2022
• Figure 53: Bayer AG: Net Revenue (by Segment), $Million, 2020-2022
• Figure 54: Bayer AG: Net Revenue (by Region), $Million, 2020-2022
• Figure 55: Bayer AG: R&D Expenditure, $Million, 2020-2022
• Figure 56: Bracco Group: Product Portfolio
• Figure 57: Fresenius SE & Co. KGaA: Product Portfolio
• Figure 58: Fresenius SE & Co. KGaA: Overall Financials, $Million, 2020-2022
• Figure 59: Fresenius SE & Co. KGaA: Net Revenue (by Region), $Million, 2020-2022
• Figure 60: Fresenius SE & Co. KGaA: R&D Expenditure, $Million, 2020-2022
• Figure 61: Guerbet: Product Portfolio
• Figure 62: Guerbet: Overall Financials, $Million, 2020-2022
• Figure 63: Guerbet: Net Revenue (by Segment), $Million, 2020-2022
• Figure 64: ulrich GmbH & Co. KG: Product Portfolio

List of Tables

• Table 1: Contrast Media Agent and Injector System Market, Key Developments Analysis, January 2018-May 2023
• Table 2: Key Questions Answered in the Report
• Table 3: Contrast Media Agent and Injector System Market, Partnerships and Business Alliances, January 2018-May 2023
• Table 4: Some of the Regulatory Approvals in Contrast Media Agent and Injector System Market, 2019-2023
• Table 5: Some of the Contrast Media Reactions and Effects
• Table 6: Guidelines for Contrast Administration and Hydration
• Table 7: Europe Contrast Media Agent and Injector System Market, Impact Analysis
• Table 8: Contrast Media Ecosystem Active Players

The Europe Contrast Media Agent and Injector System Market Expected to Reach $2,740.6 Million by 2026

Introduction to Europe Contrast Media Agent and Injector System Market

The Europe contrast media agent and injector system market was valued at $2,141.5 million in 2022 and is expected to reach $2,740.6 million by 2026, growing at a CAGR of 6.36% during the forecast period 2022-2026. The market is driven due to factors like rising cases of cancer and cardiovascular diseases, which result in higher demand for contrast media agents, injector systems, and image-guided diagnostic procedures.

Market Introduction

The Europe Contrast Media Agent and Injector System market is witnessing robust growth driven by factors such as the increasing prevalence of chronic diseases, rising demand for diagnostic imaging procedures, and advancements in medical imaging technologies. Contrast media agents and injector systems play a crucial role in enhancing the visibility of anatomical structures during imaging procedures such as CT scans, MRI scans, and angiography. With a growing aging population and rising healthcare expenditures, there is a heightened emphasis on early disease detection and accurate diagnosis, further fueling the demand for contrast media agents and injector systems in Europe. Additionally, ongoing research and development activities aimed at improving imaging techniques and patient outcomes are expected to drive market growth. Regulatory initiatives aimed at ensuring patient safety and the availability of innovative imaging solutions also contribute to market expansion in the region.

Market Segmentation:

Segmentation 1: by Product

• Contrast Media Agents
• Injector Systems

Segmentation: Injector Systems (by Product)

• Injector
• Consumables and Accessories

Segmentation 2: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Growth/Marketing Strategy: The Europe contrast media agent and injector system market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint ventures.

Competitive Strategy: The Europe contrast media agent and injector system market consists of various leading manufacturers, small-medium enterprises, and emerging startups. With the increasing demand for advanced devices, companies can expand their presence in the market through different strategic approaches. Some of the strategies followed by the leading contributors are the launch of new products, mergers and acquisitions, and regulatory and legal approvals

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Some of the prominent names established in this market are:

• Bayer AG
• Bracco Group
• Guerbet
• ulrich GmbH & Co. KG

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1 Markets

• 1.1 Market Outlook
  • 1.1.1 Product Definition
  • 1.1.2 Inclusion and Exclusion Criteria
  • 1.1.3 Key Findings
• 1.2 Market Overview
• 1.3 Industry Outlook
  • 1.3.1 Regulatory and Legal Requirements and Framework
    • 1.3.1.1 Regulatory and Legal Requirements and Framework in Europe
  • 1.3.2 Patent Analysis
    • 1.3.2.1 Patent Filing Trend (by Year)
    • 1.3.2.2 Patent Filing Trend (by Country)
  • 1.3.3 Key Trends
    • 1.3.3.1 Nanoparticle-Based Contrast Agents
    • 1.3.3.2 Development of Safer Contrast Media Agent
    • 1.3.3.3 Partnerships and Business Alliances among Players for Strong Foothold in Different Regions
• 1.4 Impact of COVID-19 on Contrast Media Agent and Injector System Market
  • 1.4.1 Pre-COVID-19 Impact
  • 1.4.2 During COVID-19 Impact
  • 1.4.3 Post-COVID-19 Impact
• 1.5 Market Dynamics
  • 1.5.1 Impact Analysis
  • 1.5.2 Market Drivers
    • 1.5.2.1 Increasing Prevalence of Cancer and Cardiovascular Diseases Leading to Upsurge Demand of Imaging with Contrast Media Agents and Injector System
    • 1.5.2.2 Upsurge in Demand for Image-Guided Diagnostics
    • 1.5.2.3 Growing Number of Regulatory Approvals
  • 1.5.3 Market Restraints
    • 1.5.3.1 Rising Health Concerns Post Usage of Contrast Media Agents in Body
  • 1.5.4 Market Opportunities
    • 1.5.4.1 IT Advances in Contrast Media Injectors

2 Region

• 2.1 Overview
• 2.2 Europe
  • 2.2.1 Key Findings
  • 2.2.2 Market Dynamics
    • 2.2.2.1 Impact Analysis
  • 2.2.3 Market Size and Forecast
    • 2.2.3.1 Europe Contrast Media Agent and Injector System Market (by Product)
      • 2.2.3.1.1 Europe Contrast Media Injector System Market (by Product)
    • 2.2.3.2 Europe Contrast Media Agent and Injector System Market (by Country)
      • 2.2.3.2.1 Germany
        • 2.2.3.2.1.1 Market Sizing and Forecast
        • 2.2.3.2.1.1.1 Germany Contrast Media Agent and Injector System Market (by Product)
        • 2.2.3.2.1.1.1.1 Germany Contrast Media Injector System Market (by Product)
      • 2.2.3.2.2 Italy
        • 2.2.3.2.2.1 Market Sizing and Forecast
        • 2.2.3.2.2.1.1 Italy Contrast Media Agent and Injector System Market (by Product)
        • 2.2.3.2.2.1.1.1 Italy Contrast Media Injector System Market (by Product)
      • 2.2.3.2.3 France
        • 2.2.3.2.3.1 Market Sizing and Forecast
        • 2.2.3.2.3.1.1 France Contrast Media Agent and Injector System Market (by Product)
        • 2.2.3.2.3.1.1.1 France Contrast Media Injector System Market (by Product)
      • 2.2.3.2.4 U.K.
        • 2.2.3.2.4.1 Market Sizing and Forecast
        • 2.2.3.2.4.1.1 U.K. Contrast Media Agent and Injector System Market (by Product)
        • 2.2.3.2.4.1.1.1 U.K. Contrast Media Injector System Market (by Product)
      • 2.2.3.2.5 Spain
        • 2.2.3.2.5.1 Market Sizing and Forecast
        • 2.2.3.2.5.1.1 Spain Contrast Media Agent and Injector System Market (by Product)
        • 2.2.3.2.5.1.1.1 Spain Contrast Media Injector System Market (by Product)
      • 2.2.3.2.6 Rest-of-Europe
        • 2.2.3.2.6.1 Market Sizing and Forecast
        • 2.2.3.2.6.1.1 Rest-of-Europe Contrast Media Agent and Injector System Market (by Product)
        • 2.2.3.2.6.1.1.1 Rest-of-Europe Contrast Media Injector System Market (by Product)

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Competitive Benchmarking
  • 3.1.1 Key Strategies and Development
    • 3.1.1.1 Regulatory and Legal Activities
    • 3.1.1.2 Partnerships, Collaborations, and Business Expansions
    • 3.1.1.3 Mergers and Acquisitions
    • 3.1.1.4 New Offerings
  • 3.1.2 Market Share Analysis
    • 3.1.2.1 Market Share Analysis, by Contrast Media Agent Market
    • 3.1.2.2 Market Share Analysis, by Contrast Media Injector System Market
• 3.2 Contrast Media Ecosystem Active Players
• 3.3 Company Profiles
  • 3.3.1 Bayer AG
    • 3.3.1.1 Company Overview
    • 3.3.1.2 Role of Bayer AG in the Contrast Media Agent and Injector System Market
    • 3.3.1.3 Financials
    • 3.3.1.4 Recent Developments
    • 3.3.1.5 Analyst Perception
  • 3.3.2 Bracco Group
    • 3.3.2.1 Company Overview
    • 3.3.2.2 Role of Bracco Group in the Contrast Media Agent and Injector System Market
    • 3.3.2.3 Recent Developments
    • 3.3.2.4 Analyst Perception
  • 3.3.3 Fresenius SE & Co. KGaA
    • 3.3.3.1 Company Overview
    • 3.3.3.2 Role of Fresenius SE & Co. KGaA in the Contrast Media Agent and Injector System Market
    • 3.3.3.3 Financials
    • 3.3.3.4 Recent Developments
    • 3.3.3.5 Analyst Perception
  • 3.3.4 Guerbet
    • 3.3.4.1 Company Overview
    • 3.3.4.2 Role of Guerbet in the Contrast Media Agent and Injector System Market
    • 3.3.4.3 Financials
    • 3.3.4.4 Recent Developments
    • 3.3.4.5 Analyst Perception
  • 3.3.5 ulrich GmbH & Co. KG
    • 3.3.5.1 Company Overview
    • 3.3.5.2 Role of ulrich GmbH & Co. KG in the Contrast Media Agent and Injector System Market
    • 3.3.5.3 Recent Developments
    • 3.3.5.4 Analyst Perception